List view / Grid view
A 2010 overview article on companion diagnostics, compiled by authors Stephen Naylor and Toby Cole, commented on the need for the companion diagnostic to fit into the logistics of the testing laboratory. The intervening five years have shown that patients are demanding more rapid and more convenient testing for diagnosis,…
All new drugs rely, to a greater or lesser extent, on pre-existing research and development. Much of this pre-existing research will have resulted in patented methods and products. A major challenge for all researchers is therefore to develop new drugs which do not infringe other company’s patents.
11 May 2015 | By Victoria White
US and EU Patent Offices have granted Domainex patents for the first generation of inhibitor compounds in its lead programme targeting IKK epsilon and TBK1.
8 April 2015 | By Victoria White
Cardio3 has received a Notice of Allowance from the USPTO for a patent application covering TCR-deficient T-Cells which are engineered to express a CAR...
18 March 2015 | By Victoria White
TxCell SA has announced that a key patent, covering its lead product Ovasave(R) in IBD, is to be granted in the US on 31 March 2015...
11 February 2015 | By Cancer-Code Corporation
Another foundation patent in the burgeoning field of bioelectronic medicine, specifically for treating cancer patients...
8 January 2015 | By SciFluor Life Sciences
SciFluor Life Sciences, LLC, an emerging clinical stage biopharmaceutical company that creates innovative therapeutics for patients with ophthalmologic and neurologic disease, announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,916,133 with claims covering the novel compound SF0034...
17 December 2014 | By MRC Technology
Structure-based drug discovery platform targets challenging GPCRs linked to human disease...
8 December 2014 | By SciFluor Life Sciences
SciFluor Life Sciences, LLC announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,901,144 with claims covering the novel compound SF0166...
24 July 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool to expand access to Gilead’s investigational drug tenofovir alafenamide...
